— U.S. FDA revises Boxed Warning to clarify that NUPLAZID can be used to treat patients with Parkinson's disease-related hallucinations and delusions who also have dementia

SAN DIEGO — September 18, 2023 – Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the U.S. Food and Drug Administration (FDA) has made two changes to the NUPLAZID label that clarify its use in patients with Parkinson's disease-related hallucinations and delusions, with or without dementia. This update is consistent with the current indication. There are no other findings or changes included as part of the label change.

The two changes include: 1) Updated...